Cornish J, Callon K E, Cooper G J, Reid I R
Department of Medicine, University of Auckland, New Zealand.
Biochem Biophys Res Commun. 1995 Feb 6;207(1):133-9. doi: 10.1006/bbrc.1995.1163.
Amylin, a 37-amino-acid peptide co-secreted with insulin from the beta-cells of the pancreatic islets, has previously been demonstrated to inhibit bone resorption in vitro. However, its effects on bone formation and bone mass have not been assessed. We report that periphysiological concentrations of amylin stimulate proliferation of fetal rat osteoblasts in vitro. When amylin is injected daily for 5 days over the calvariae of adult mice in vivo, there are substantial increases in histomorphometric indices of bone formation, a reduction in bone resorption, and a significant increase in mineralized bone area. Equimolar doses of calcitonin in this in vivo model produced an inhibition of bone resorption but no significant effect on bone area. These findings support a role for amylin as a physiological regulator of bone and suggest that it should also be evaluated as a potential treatment for osteoporosis.
胰淀素是一种由胰岛β细胞与胰岛素共同分泌的含37个氨基酸的肽，此前已证明它在体外可抑制骨吸收。然而，其对骨形成和骨量的影响尚未得到评估。我们报告称，生理浓度的胰淀素在体外可刺激胎鼠成骨细胞增殖。当在成年小鼠颅骨上每日注射胰淀素，持续5天时，骨形成的组织形态计量学指标显著增加，骨吸收减少，矿化骨面积显著增加。在此体内模型中，等摩尔剂量的降钙素可抑制骨吸收，但对骨面积无显著影响。这些发现支持了胰淀素作为骨的生理调节因子的作用，并表明它也应作为骨质疏松症的一种潜在治疗方法进行评估。
